Colorectal cancer - Is there an alternative to 5-FU?

European Journal of Cancer Part A

Volumn 33, Issue 4, 1997, Pages 536-541

  Bleiberg, H ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; EDRECOLOMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METESIND GLUCURONATE; NOLATREXED; OXALIPLATIN; PEMETREXED; RALTITREXED;

ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMATITIS;

EID: 0030966645     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00481-9     Document Type: Review

References (32)

1. Estève J, Kricker A, Ferlay J, Parkin DM. Facts and Figures of Cancer in the European Community. Lyon, International Agency for Research on Cancer, 1993.
2. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994, 44, 7-26.
3. Cunningham D, Findlay M. The chemotherapy of colorectal cancer can no longer be ignored. Eur J Cancer 1993, 29A, 2077-2079.
4. Mamounas EP, Rockette H, Jones J, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs Dukes' C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04). Proc Am Soc Clin Oncol 1996, 15, 205 (abstract 461).
5. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by folinic acid in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
6. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of signifcant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7, 1407-1417.
7. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with folinic acid: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991, 9, 1967-1972.
8. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and folinic acid in the treatment of advanced colorectal cancer. J Clin Oncol 1994, 12, 14-20.
9. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 1995, 13, 1303-1311.
10. Advanced Colorectal Cancer Meta-Analysis Project. Metaanalysis of randomised trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994, 12, 960-969.
11. Seifert P, Baker LH, Reed ML, Venkevicius K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975, 36, 123-128.
12. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus administration schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989, 7, 425-432.
13. de Gramont A, Bossett JF, Milan C, et al. A prospectively randomized trial comparing 5FU bolus with low-dose folinic acid (FUFOL1d) and 5FU bolus plus continuous infusion with high-dose folinic acid (LV5FU2) for advanced colorectal cancer. Proc Am Soc Clin Oncol 1995, 14, 194 (abstract 455).
14. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992, 69, 893-900.
15. Lévi FA, Zidani R, Vannetzel J-M, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multiinstitutional trial. J Natl Cancer Inst 1994, 86, 1608-1617.
16. Lévi F, Giacchetti S, Adam R, Zidani R, Metzger G, Misset J-L. Chronomodulation of chemotherapy against metastatic colorectal cancer. Eur J Cancer 1995, 31A, 1264-1270.
17. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993, 306, 752-755.
18. Nordic Gastrointestinal Tumor Adjuvant Therapy group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992, 10, 904-911.
19. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994, 343, 1177-1183.
20. Shimada Y, Yashino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993, 11, 909-913.
21. Conti JA, Kemeny N, Saltz L, Tong W, Chou TC, Pulliam M. Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer (CRC) (abstract 565). 30th Annual Meeting of the Am Soc Clin Oncol, Dallas, Texas, May 14-17, 1994, 13, 195.
22. Pitot HC, Wender D, O'Connell MJ, Wieand HS, Mailliard JA. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study (abstract 573). 30th Annual Meeting of the Am Soc Clin Oncol, Dallas, Texas, May 14-17, 1994, 13, 197.
23. Rothenberg ML, Eckardt JR, Burris III HA, et al. Irinotecan (CPT-11) as second line therapy for PTS with 5-FU-refractory colorectal cancer (abstract 578). 30th Annual Meeting of the Am Soc Clin Oncol, Dallas, Texas, May 14-17, 1994, 13, 198.
24. Rougier P, Bugat R, Brunet P, et al. Clinical efficacy of CPT-11 in patients with inoperable advanced colorectal cancer (CRC): results of a multicentric open phase II study (abstract S775). 5th International Congress of Anti-cancer Chemotherapy, Paris, France, Jan/Feb 31 3, 1995, 288.
25. Bugat R. CPT-11 in the treatment of colorectal cancer (CRC): safety profile (abstract S778). 5th International Congress of Anti-cancer Chemotherapy, Paris, France, Jan/Feb 31-3, 1995, 289.
26. R) in 5-FU refractory patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1995, 14, 209 (abstract 514).
27. de Gramont A, Gastiaburu J, Tournigand C, et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48h infusion in pretreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1994, 13, 220 (abstract 666).
28. R) therapy. Proc Am Assoc Cancer Res 1993, 34, 2421 (abstract).
29. R (ZD1694), a novel thymidylate synthase inhibitor has substantial activity in the treatment of patients with advanced colorectal cancer. J Clim Oncol 1996, 14, 716-721.
30. Cunningham D, Zalcberg JR, Rath U, et al. Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995, 31A, 1945-1954.
31. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345, 939-944.
32. Moertel CG, Fleming TR, MacDonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122, 321-326.